cladribine has been researched along with Obesity in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
1 other study(ies) available for cladribine and Obesity
Article | Year |
---|---|
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |